Journal of Traditional Chinese Medicine ›› 2026, Vol. 46 ›› Issue (5): 1082-1095.DOI: 10.19852/j.cnki.jtcm.2026.05.003
• Original Articles • Previous Articles Next Articles
LU Yao1, WEI Lini1,2, WANG Ruiqi1, YANG Jingwen1, ZHANG Kaiqi1, ZHAO Ning1, LI Li1(
)
Received:2025-05-28
Accepted:2025-12-25
Online:2026-10-15
Published:2026-10-09
Contact:
Researcher LI Li, Institute of Clinical Basic Medicine of Traditional Chinese Medicine, Chinese Academy of Traditional Chinese Medicine, Beijing 100010, China, lilylove1116@126.com,Telephone: +86-15810212686
Supported by:LU Yao, WEI Lini, WANG Ruiqi, YANG Jingwen, ZHANG Kaiqi, ZHAO Ning, LI Li. Regulatory effect of baicalein on intestinal ribosome biogenesis in mice with asthma[J]. Journal of Traditional Chinese Medicine, 2026, 46(5): 1082-1095.
Figure 1 Effect of BAI on airway inflammation, as determined by HE staining, mucus secretion, as determined by PAS, and inflammatory cytokine levels A: HE staining is used to detect pulmonary inflammatory infiltration (× 100); B: PAS staining is used to identify mucus secretion in lung tissue (× 100); C: HE staining is used to examine inflammatory infiltration in colon tissue (× 100); D: PAS staining is used to check the secretion of colonic mucus (× 100). A1, B1, C1, D1: Control group; A2, B2, C2, D2: Model group; A3, B3, C3, D3: BAI (L) group; A4, B4, C4, D4: BAI (M) group; A5, B5, C5, D5: BAI (H) group; A6, B6, C6, D6: Montelukast group. Control: treated only with physiological saline solution; model: treated with OVA and physiological saline; BAI (L): treated with OVA and 10 mg/kg BAI; BAI (M): treated with OVA and 20 mg/kg BAI. BAI (H): treated with OVA and 40 mg/kg BAI. BAI (L): Baicalein (low-dose); BAI (M): Baicalein (Medium-dose); BAI (H): Baicalein (high-dose). The data were analyzed with one-way analysis of variance, and the statistically significant effects were compared with Tukey’s multiple range test. HE: hematoxylin and eosin; PAS: periodic acid-schiff; OVA: ovalbumin. All the data are presented as the mean ± standard deviations ($\bar{x}$ ± s) (n = 3).
| Group | n | Dose (mg·kg-1·d-1) | HE staining score | PAS staining score |
|---|---|---|---|---|
| Control | 3 | - | 0.83±0.41 | 2.14±0.22 |
| Model | 3 | - | 10.83±1.83a | 4.36±0.42a |
| BAI (L) | 3 | 10 | 8.83±1.94 | 3.21±0.13b |
| BAI (M) | 3 | 20 | 6.67±1.37 | 3.10±0.20b |
| BAI (H) | 3 | 40 | 3.83±0.75b | 2.76±0.32b |
| Montelukast | 3 | 10 | 3.83±0.75b | 2.79±0.43b |
Table 1 Comparison of pathological scores of lung tissue in different groups of mice ($\bar{x}$ ± s)
| Group | n | Dose (mg·kg-1·d-1) | HE staining score | PAS staining score |
|---|---|---|---|---|
| Control | 3 | - | 0.83±0.41 | 2.14±0.22 |
| Model | 3 | - | 10.83±1.83a | 4.36±0.42a |
| BAI (L) | 3 | 10 | 8.83±1.94 | 3.21±0.13b |
| BAI (M) | 3 | 20 | 6.67±1.37 | 3.10±0.20b |
| BAI (H) | 3 | 40 | 3.83±0.75b | 2.76±0.32b |
| Montelukast | 3 | 10 | 3.83±0.75b | 2.79±0.43b |
| Group | n | sRaw (cm H2O.s) | |||
|---|---|---|---|---|---|
| Mch (0 mg/mL) | Mch (3.125 mg/mL) | Mch (6.25 mg/mL) | Mch (12.5 mg/mL) | ||
| Control | 4 | 2.98±0.90 | 3.04±0.86 | 3.63±0.63 | 4.46±0.76 |
| Model | 4 | 6.16±1.56a | 6.09±0.73a | 7.44±1.52a | 9.24±0.12a |
| BAI (L) | 4 | 5.24±0.55 | 5.45±0.29 | 6.13±0.17 | 7.49±0.84b |
| BAI (M) | 4 | 4.21±0.39b | 4.94±0.48 | 5.52±0.47b | 6.33±0.54b |
| BAI (H) | 4 | 3.68±0.72b | 4.68±0.75 | 5.25±0.68b | 5.48±0.46b |
| Montelukast | 4 | 3.56±0.68b | 4.07±1.40b | 4.56±0.93b | 5.21±1.04b |
Table 2 Special airway resistance of mice in different groups under different concentrations of Mch ($\bar{x}$± s)
| Group | n | sRaw (cm H2O.s) | |||
|---|---|---|---|---|---|
| Mch (0 mg/mL) | Mch (3.125 mg/mL) | Mch (6.25 mg/mL) | Mch (12.5 mg/mL) | ||
| Control | 4 | 2.98±0.90 | 3.04±0.86 | 3.63±0.63 | 4.46±0.76 |
| Model | 4 | 6.16±1.56a | 6.09±0.73a | 7.44±1.52a | 9.24±0.12a |
| BAI (L) | 4 | 5.24±0.55 | 5.45±0.29 | 6.13±0.17 | 7.49±0.84b |
| BAI (M) | 4 | 4.21±0.39b | 4.94±0.48 | 5.52±0.47b | 6.33±0.54b |
| BAI (H) | 4 | 3.68±0.72b | 4.68±0.75 | 5.25±0.68b | 5.48±0.46b |
| Montelukast | 4 | 3.56±0.68b | 4.07±1.40b | 4.56±0.93b | 5.21±1.04b |
| Group | n | IL-4 | IL-5 | IL-13 | TSLP | IL-25 | IL-33 |
|---|---|---|---|---|---|---|---|
| Control | 6 | 71.5±20.5 | 83.2±2.9 | 39.6±3.1 | 82.0±2.6 | 42.9±4.2 | 49.4±3.6 |
| Model | 6 | 629.3±66.6a | 596.7±76.4a | 141.8±14.8a | 390.4±28.2a | 232.1±15.2a | 318.3±6.0a |
| BAI (L) | 6 | 220.1±67.1b | 428.6±12.3b | 185.3±7.9 | 285.0±4.9b | 159.1±7.4b | 220.7±8.5b |
| BAI (M) | 6 | 174.9±46.2b | 339.5±11.4b | 101.3±8.2b | 184.9±3.8b | 132.3±5.9b | 145.2±1.7b |
| BAI (H) | 6 | 70.4±17.0b | 203.1±49.5b | 87.6±11.8b | 109.9±8.8b | 76.6±3.7b | 108.9±11.7b |
| Montelukast | 6 | 124.7±72.7b | 246.8±32.7b | 126.1±2.4b | 162.7±10.0b | 98.7±2.5b | 110.1±8.6b |
Table 3 Effect of baicalein on the levels of IL-4, IL-5, and IL-13 in mouse lung tissue ((pg/mL, $\bar{x}$ ± s)
| Group | n | IL-4 | IL-5 | IL-13 | TSLP | IL-25 | IL-33 |
|---|---|---|---|---|---|---|---|
| Control | 6 | 71.5±20.5 | 83.2±2.9 | 39.6±3.1 | 82.0±2.6 | 42.9±4.2 | 49.4±3.6 |
| Model | 6 | 629.3±66.6a | 596.7±76.4a | 141.8±14.8a | 390.4±28.2a | 232.1±15.2a | 318.3±6.0a |
| BAI (L) | 6 | 220.1±67.1b | 428.6±12.3b | 185.3±7.9 | 285.0±4.9b | 159.1±7.4b | 220.7±8.5b |
| BAI (M) | 6 | 174.9±46.2b | 339.5±11.4b | 101.3±8.2b | 184.9±3.8b | 132.3±5.9b | 145.2±1.7b |
| BAI (H) | 6 | 70.4±17.0b | 203.1±49.5b | 87.6±11.8b | 109.9±8.8b | 76.6±3.7b | 108.9±11.7b |
| Montelukast | 6 | 124.7±72.7b | 246.8±32.7b | 126.1±2.4b | 162.7±10.0b | 98.7±2.5b | 110.1±8.6b |
| Group | n | Dose (mg·kg-1·d-1) | HE staining score | PAS staining score |
|---|---|---|---|---|
| Control | 3 | - | 0.0±0.0 | 7.9±1.6 |
| Model | 3 | - | 10.6±2.1a | 17.2±0.8a |
| BAI (L) | 3 | 10 | 10.6±1.1 | 16.2±1.9 |
| BAI (M) | 3 | 20 | 5.0±0.7 | 13.1±1.3 |
| BAI (H) | 3 | 40 | 1.2±0.8b | 11.2±1.2b |
| Montelukast | 3 | 10 | 1.4±0.6b | 10.5±0.7b |
Table 4 Comparison of pathological scores of lung tissue in different groups of mice ($\bar{x}$ ± s)
| Group | n | Dose (mg·kg-1·d-1) | HE staining score | PAS staining score |
|---|---|---|---|---|
| Control | 3 | - | 0.0±0.0 | 7.9±1.6 |
| Model | 3 | - | 10.6±2.1a | 17.2±0.8a |
| BAI (L) | 3 | 10 | 10.6±1.1 | 16.2±1.9 |
| BAI (M) | 3 | 20 | 5.0±0.7 | 13.1±1.3 |
| BAI (H) | 3 | 40 | 1.2±0.8b | 11.2±1.2b |
| Montelukast | 3 | 10 | 1.4±0.6b | 10.5±0.7b |
Figure 2 Data quality monitoring and bioinformatics analysis of DEPs by category A: the ten most significantly enriched terms of the GO hierarchy and the number of involved proteins in a term; B: enriched KEGG pathways of the DEPs. The number of proteins involved and corresponding P values are shown on the right side of the column; C: PPI analysis and key node protein screening were performed with STRING and Cytoscape; D: expression heatmap of proteins involved in ribosomal biological processes; E: correlation analysis of 8 ribosome-related proteins and inflammatory factors; F: IPA to predict biological effects based on differential expression profiles in the data. The red boxes in Figures A and B, as well as the blue boxes in Figure F, refer to the content related to "ribosome biogenesis". DEPs: differentially expressed proteins; GO: gene ontology; KEGG: kyoto encyclopedia of genes and genomes; PPI: protein-protein interaction; STRING: Search Tool for the Retrieval of Interacting Genes/Proteins; IPA: ingenuity pathway analysis; BP: biological process; CC: cellular component; MF: molecular function; MRPS9: small ribosomal subunit protein uS9m; RPL28: ribosomal protein L28; RPL32: ribosomal protein L32; RPS15A: ribosomal protein S15A; RPS23: ribosomal protein S23; POLR1C: RNA polymerase I and III subunit C; RPL23A: ribosomal protein L23A; RPS25: ribosomal protein S25; IL: interleukin; TSLP: thymic stromal lymphopoietin.
| Drug | Targets | PDB ID | Binding affinity (kcal/mol) |
|---|---|---|---|
| Baicalein | RPL28 | 6IP8 | -7.9 |
| Baicalein | POLR1C | 7OB9 | -8.6 |
| Baicalein | RPS15A | 5K0Y | -6.8 |
| Baicalein | RPS23 | 3MGU | -8.8 |
| Baicalein | RPL23A | 1G62 | -10.5 |
| Baicalein | RPS25 | 6ZOL | -9 |
| Baicalein | RPL32 | 1T0K | -7.2 |
| Baicalein | MRPS9 | 5AJ3 | -7.5 |
Table 5 Molecular docking of 8 proteins related to the biological functions of ribosomes to baicalein
| Drug | Targets | PDB ID | Binding affinity (kcal/mol) |
|---|---|---|---|
| Baicalein | RPL28 | 6IP8 | -7.9 |
| Baicalein | POLR1C | 7OB9 | -8.6 |
| Baicalein | RPS15A | 5K0Y | -6.8 |
| Baicalein | RPS23 | 3MGU | -8.8 |
| Baicalein | RPL23A | 1G62 | -10.5 |
| Baicalein | RPS25 | 6ZOL | -9 |
| Baicalein | RPL32 | 1T0K | -7.2 |
| Baicalein | MRPS9 | 5AJ3 | -7.5 |
Figure 3 MD simulation analysis of the RPS25-Baicalein, RPL23A-Baicalein, and POLR1C-Baicalein complexes for more than 100 ns. A: RMSD image; B: Rg image; C: SASA image; D: image showing the number of Hbonds; E: RMSF image (RPL23A-Baicalein); F: RMSF image (RPS25-Baicalein); G: RMSF image (POLR1C-Baicalein). E1: RPL23A-Baicalein-Chain-A; E2: RPL23A-Baicalein-Chain-B; F1: RPS25-Baicalein-Chain-A; F2: RPS25-Baicalein-Chain-B; F3: RPS25-Baicalein-Chain-C; F4: RPS25-Baicalein-Chain-D. RMSD: the root mean square deviation; Rg: the radius of gyration; SASA: solvent accessible surface area; RMSF: the root mean square fluctuation; POLR1C: RNA polymerase I and III subunit C; RPL23A: ribosomal protein L23A; RPS25: ribosomal protein S25.
Figure 4 Baicalein decreased ribosome biogenesis in the colon tissues of mice with allergic asthma A: identification of POLR1C expression in colon tissue by immunohistochemical staining (× 200), scale bar: 100 μm; B: identification of RPS25 expression in colon tissue by immunohistochemical staining (× 200), scale bar: 100 μm; C: identification of RPL23A expression in colon tissue by immunohistochemical staining (× 200), scale bar: 100 μm. A1, B1, C1: Control group; A2, B2, C2: Model group; A3, B3, C3: BAI (H) group; A4, B4, C4: Montelukast group. Control: treated only with physiological saline solution; model: treated with OVA and physiological saline; BAI (H): treated with OVA and 40 mg/kg BAI. BAI (H): Baicalein (high-dose); OVA: ovalbumin; POLR1C: RNA polymerase I and III subunit C; RPL23A: ribosomal protein L23A; RPS25: ribosomal protein S25.
| Group | n | POLR1C/AOD | RPS25/AOD | RPL23A/AOD |
|---|---|---|---|---|
| Control | 3 | 0.006±0.000 | 0.018±0.000 | 0.020±0.000 |
| Model | 3 | 0.024±0.000a | 0.061±0.020a | 0.073±0.020a |
| BAI (H) | 3 | 0.008±0.000b | 0.020±0.000b | 0.031±0.010b |
| Montelukast | 3 | 0.008±0.000b | 0.032±0.010 | 0.039±0.010 |
Table 6 Staining intensity of POLR1C, RPS25, and RPL23A proteins in colon tissue of mice in each group (scores, $\bar{x}$ ± s)
| Group | n | POLR1C/AOD | RPS25/AOD | RPL23A/AOD |
|---|---|---|---|---|
| Control | 3 | 0.006±0.000 | 0.018±0.000 | 0.020±0.000 |
| Model | 3 | 0.024±0.000a | 0.061±0.020a | 0.073±0.020a |
| BAI (H) | 3 | 0.008±0.000b | 0.020±0.000b | 0.031±0.010b |
| Montelukast | 3 | 0.008±0.000b | 0.032±0.010 | 0.039±0.010 |
| [1] | Palaniyandi S, Rajendrakumar AM, Periasamy S, et al. TRPV4 is dispensable for the development of airway allergic asthma. Lab Invest 2020; 100: 265-73. |
| [2] | Rajvanshi N, Kumar P, Goyal JP. Global initiative for asthma guidelines 2024: an update. Indian Pediatr 2024; 61: 781-6. |
| [3] | Kulkarni NS, Hollins F, Sutcliffe A, et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol 2010; 126: 61-9. |
| [4] | Song XL, Liang J, Lin SZ, et al. Gut-lung axis and asthma: a historical review on mechanism and future perspective. Clin Transl Allergy 2024; 14: e12356. |
| [5] | Zhang D, Li S, Wang N, et al. The cross-talk between gut microbiota and lungs in common lung diseases. Front Microbiol 2020; 11: 301. |
| [6] | Tan TG, Sefik E, Gevazatorsky N, et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci U S A 2016; 113: E8141-50. |
| [7] | Henrick BM, Rodriguez L, Lakshmikanth T, et al. Bifidobacteria-mediated immune system imprinting early in life. Cell 2021; 184: 3884-98. |
| [8] | Huang Y, Mao K, Chen X, et al. S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense. Science 2018; 359: 114-9. |
| [9] | Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55-63. |
| [10] | Ruan Y, Yuan PP, Li PY, et al. Tingli Dazao Xiefei decoction ameliorates asthma in vivo and in vitro from lung to intestine by modifying NO-CO metabolic disorder mediated inflammation, immune imbalance, cellular barrier damage, oxidative stress and intestinal bacterial disorders. J Ethnopharmacol 2023; 313: 116503. |
| [11] | Ousingsawat J, Centeio R, Reyne N, et al. Inhibition of mucus secretion by niclosamide and benzbromarone in airways and intestine. Sci Rep 2024; 14: 1464. |
| [12] | Bao K, Gu X, Song Y, et al. TCF-1 and TOX regulate the memory formation of intestinal group 2 innate lymphoid cells in asthma. Nat Commun 2024; 15: 7850. |
| [13] | Zhang Y, Li T, Yuan H, Pan W, Dai Q. Correlations of inflammatory factors with intestinal flora and gastrointestinal incommensurate symptoms in children with asthma. Med Sci Monit 2018; 24: 7975-9. |
| [14] | Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science 2016; 352: 539-44. |
| [15] | Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-6. |
| [16] | Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5. |
| [17] | Shi CY, Yu CH, Yu WY, Ying HZ. Gut-lung microbiota in chronic pulmonary diseases: evolution, pathogenesis, and therapeutics. Can J Infect Dis Med Microbiol 2021; 2021: 9278441. |
| [18] | Lai HC, Lin TL, Chen TW, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut 2022; 71: 309-21. |
| [19] | Adam L, Stanifer M, Springer F, et al. Transcriptomics-inferred dynamics of SARS-CoV-2 interactions with host epithelial cells. Sci Signal 2023; 16: eabl8266. |
| [20] | Shen X, Liang M, Chen X, et al. Cutting edge: core binding factor β is required for group 2 innate lymphoid cell activation. J Immunol 2019; 202: 1669-73. |
| [21] | Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008; 111: 4892-901. |
| [22] | Wei L, Zhang L, Zhang Y, et al. Intestinal Escherichia coli and related dysfunction as potential targets of Traditional Chinese Medicine for respiratory infectious diseases. J Ethnopharmacol 2023; 313: 116381. |
| [23] | Tuli HS, Aggarwal V, Kaur J, et al. Baicalein: a metabolite with promising antineoplastic activity. Life Sci 2020; 259: 118183. |
| [24] | Xu T, Ge X, Lu C, et al. Baicalein attenuates OVA-induced allergic airway inflammation through the inhibition of the NF-κB signaling pathway. Aging-Us 2019; 11: 9310-27. |
| [25] | Wang D, Nasab EM, Athari SS. Study effect of Baicalein encapsulated/loaded Chitosan-nanoparticle on allergic Asthma pathology in mouse model. Saudi J Biol Sci 2021; 28: 4311-7. |
| [26] | Peng W, Xia Q, Zhang Y, Cao D, Zheng X. VEGF and EGFR signaling pathways are involved in the baicalein attenuation of OVA-induced airway inflammation and airway remodeling in mice. Respir Res 2024; 25: 10. |
| [27] | Bui TT, Piao CH, Song CH, et al. Baicalein, wogonin, and Scutellaria baicalensis ethanol extract alleviate ovalbumin-induced allergic airway inflammation and mast cell-mediated anaphylactic shock by regulation of Th1/Th2 imbalance and histamine release. Anat Cell Biol 2017; 50: 124-34. |
| [28] | Li YY, Wang XJ, Su YL, et al. Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s. Acta Pharmacol Sin 2022; 43: 1495-507. |
| [29] | Zhou S, Yin X, Liang Z, et al. Antifibrotic activities of Scutellariae Radix extracts and flavonoids: Comparative proteomics reveals distinct and shared mechanisms. Phytomedicine 2022; 100: 154049. |
| [30] | Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1577-9. |
| [31] | Mcgrath JC, Drummond GB, Mclachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 2010; 160: 1573-6. |
| [32] | Lazarinis N, Bood J, Gomez C, et al. Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor. J Allergy Clin Immunol 2018; 142: 1080-9. |
| [33] | Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998; 53: 849-56. |
| [34] | Jia K, Wang Y, Tong X, Wang R. KGF is delivered to inflammatory and induces the epithelial hyperplasia in trinitrobenzene sulfonic acid-induced ulcerative colitis rats. Drug Des Devel Ther 2020; 14: 217-31. |
| [35] | Guo S, Shi Y, Xu A, Wang Y, Xu P. Liubao tea extract ameliorates ovalbumin-induced allergic asthma by regulating gut microbiota in mice. Food Funct 2023; 14: 10605-16. |
| [36] | Rakhshani H, Dehghanian E, Rahati A. Enhanced GROMACS: toward a better numerical simulation framework. J Mol Model 2019; 25: 355. |
| [37] | Wang X, Kaiser H, Kvist-Hansen A, et al. IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis. Int J Mol Sci 2022; 23: 555. |
| [38] | Shen L, Yang A, Chen X, et al. Proteomic profiling of cerebrum mitochondria, myelin sheath, and synaptosome revealed mito-chondrial damage and synaptic impairments in association with 3 x Tg-AD mice model. Cell Mol Neurobiol 2022; 42: 1745-63. |
| [39] | Nair PM, Starkey MR, Haw TJ, et al. Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice. Allergy 2017; 72: 1891-903. |
| [40] | Sharma S, Litonjua A. Asthma, allergy, and responses to methyl donor supplements and nutrients. J Allergy Clin Immunol 2014; 133: 1246-54. |
| [41] | Chinnapaiyan S, Dutta RK, Nair M, et al. TGF-β1 increases viral burden and promotes HIV-1 latency in primary differentiated human bronchial epithelial cells. Sci Rep 2019; 9: 12552. |
| [42] | Hong H-J, Kim E, Jung MY, Kim S, Kim TS. AIMP 1 deficiency enhances airway hyperreactivity in mice via increased TH2 immune responses. Clin Immunol 2012; 143: 256-65. |
| [43] | Esnault S, Kelly EAB, Shen ZJ, et al. IL-3 maintains activation of the p90S6K/RPS6 pathway and increases translation in human eosinophils. J Immunol 2015; 195: 2529-39. |
| [44] | Zhao J, Zhang Q, Yao D, et al. Prenatal LPS exposure promotes allergic airway inflammation via long coding RNA NONMMUT033452.2, and protein binding partner, Eef1D. Am J Respir Cell Mol Biol 2023; 68: 610-24. |
| [45] | Zhou LM, Goldsmith AM, Bentley JK, et al. 4E-binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol 2005; 33: 195-202. |
| [46] | Li C, Wen R, Liu D, et al. Assessment of the potential of sarcandra glabra (thunb.) Nakai. in treating ethanol-induced gastric ulcer in rats based on metabolomics and network analysis. Front Pharmacol 2022; 13: 810344. |
| [47] | Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol 2015; 5: S2-6. |
| [48] | Demirci M, Tokman HB, Uysal HK, et al. Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. Allergol Immunopathol (Madr) 2019; 47: 365-71. |
| [49] | Mabalirajan U, Ahmad T, Rehman R, et al. Baicalein reduces airway injury in allergen and IL-13 induced airway inflammation. PloS ONE 2013; 8: e62916. |
| [50] | Hu T, Zhu Y, Zhou X, et al. Baicalein ameliorates SEB-induced acute respiratory distress syndrome in a microbiota-dependent manner. Phytomedicine 2024; 135: 156049. |
| [51] | Shankar A, Mcalees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol 2022; 150: 266-76. |
| [52] | Kianmehr M, Haghmorad D, Nosratabadi R, et al. The effect of zataria multiflora on Th1/Th2 and Th17/T regulatory in a mouse model of allergic asthma. Front Pharmacol 2017; 8: 458. |
| [53] | Hammad H, Lambrecht BN. The basic immunology of asthma. Cell 2021; 184: 2521-2. |
| [54] | Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463: 540-4. |
| [55] | Wallrapp A, Riesenfeld SJ, Burkett PR, Kuchroo VK. Type 2 innate lymphoid cells in the induction and resolution of tissue inflammation. Immunol Rev 2018; 286: 53-73. |
| [56] | Salmond RJ, Mirchandani AS, Besnard AG, et al. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol 2012; 130: 1159-1166.e6. |
| [57] | Chua HH, Chou HC, Tung YL, et al. Intestinal dysbiosis featuring abundance of ruminococcus gnavus associates with allergic diseases in infants. Gastroenterology 2018; 154: 154-67. |
| [58] | Wen Y, Emontzpohl C, Xu L, et al. Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis. Hepatology 2023; 77: 1580-92. |
| [59] | Ma PJ, Wang MM, Wang Y. Gut microbiota: a new insight into lung diseases. Biomed Pharmacother 2022; 155: 113810. |
| [60] | Zakeri A, Russo M. Dual role of toll-like receptors in human and experimental asthma models. Front Immunol 2018; 9: 1027. |
| [61] | Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol 2019; 20: 1279-90. |
| [62] | Barcik W, Pugin B, Westermann P, et al. Histamine-secreting microbes are increased in the gut of adult asthma patients. J Allergy Clin Immunol 2016; 138: 1491-4. |
| [63] | He Q, Liu C, Shen L, et al. Theory of the exterior-interior relationship between the lungs and the large intestine to explore the mechanism of Eriobotrya japonica leaf water extract in the treatment of cough variant asthma. J Ethnopharmacol 2021; 281: 114482. |
| [64] | Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer 2018; 18: 51-63. |
| [65] | Zhang D, Pu X, Zheng M, Li G, Chen J. Employing a synergistic bioinformatics and machine learning framework to elucidate biomarkers associating asthma with pyrimidine metabolism genes. Respir Res 2024; 25: 327. |
| [66] | Watt KEN, Macintosh J, Bernard G, Trainor PA. RNA Polymerases I and III in development and disease. Semin Cell Dev Biol 2023; 136: 49-63. |
| [67] | Mersakova S, Marcinek J, Brany D, et al. Establishment of coala: a novel 3D and 2D cancer cell line derived from colorectal cancer liver metastasis. Hum Cell 2025; 38: 137. |
| [68] | Jiang J, Qi T, Li L, et al. MRPS9-mediated regulation of the PI3K/Akt/mTOR pathway inhibits neuron apoptosis and protects ischemic stroke. J Mol Neurosci 2024; 74: 23. |
| [69] | Flaquer A, Heinzmann A, Rospleszcz S, et al. Association study of mitochondrial genetic polymorphisms in asthmatic children. Mitochondrion 2014; 14: 49-53. |
| [70] | Xie J, Zhang W, Liang X, et al. RPL 32 promotes lung cancer progression by facilitating p53 degradation. Mol Ther Nucleic Acids 2020; 21: 75-85. |
| [71] | Li L-S, Tong Y, Yuan C, Zhang W. Evaluation of diagnostic value and Mendelian randomization study of appendicitis hub genes obtained by WGCNA analysis. Medicine 2024; 103: e39307. |
| [72] | Zheng K, Cai Y, Lei Y, et al. Proteomic characteristics of beryllium sulfate-induced differentially expressed proteins in rats. Toxicol Res 2021; 10: 962-74. |
| [73] | Chen J, Wei Y, Feng Q, et al. Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. Int J Oncol 2016; 48: 1628-38. |
| [74] | Farre-Garros R, Lee JY, Natanek SA, et al. Quadriceps miR-542-3p and-5p are elevated in COPD and reduce function by inhibiting ribosomal and protein synthesis. J Appl Physiol 2019; 126: 1514-24. |
| [75] | Maeda Y, Kurakawa T, Umemoto E, et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 2016; 68: 2646-61. |
| [76] | Hsu CH, Hsu CW, Hsueh C, et al. Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol Cell Proteomics 2016; 15: 2396-410. |
| [77] | Kim CW, Cha JM, Kwak MS. Identification of potential biomarkers and biological pathways for poor clinical outcome in mucinous colorectal adenocarcinoma. Cancers (Basel) 2021; 13: 3280. |
| [78] | You A, Tian W, Yuan H, et al. TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern. Oncogene 2022; 41: 3925-38. |
| [79] | Burrows K, Ngai L, Chiaranunt P, et al. A gut commensal protozoan determines respiratory disease outcomes by shaping pulmonary immunity. Cell abbreviation 2025; 188: 316-30. |
| [80] | Liao G, Yan Q, Zhang M, et al. Integrative analysis of network pharmacology and proteomics reveal the protective effect of Xiaoqinglong decotion on neutrophilic asthma. J Ethnopharmacol. 2024; 330: 118102. |
| [1] | WANG Bingyu, JIN Fangfang, GAO Jiawei, YANG Liuxin, ZHANG Yali, YUAN Xingxing, ZHANG Yang. Acupuncture reduces sedative and anaesthetic consumption and improves pain tolerance in patients undergoing colonoscopy: a Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2024, 44(6): 1091-1103. |
| [2] | LI Miao, ZHENG Jialu, WANG Shuangshuang, CHEN Lei, PENG Xiao, CHEN Jinfang, AN Hongmei, HU Bing. Tenglong Buzhong granules (藤龙补中颗粒) inhibits the growth of SW620 human colon cancer in vivo [J]. Journal of Traditional Chinese Medicine, 2022, 42(5): 701-706. |
| [3] | You WU, Yuli HU, Wei LIU, Boju SUN, Chengfei ZHANG, Lili WU, Tonghua LIU. Flavonoids from traditional Chinese herbs for diabetes in rats: a network Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2022, 42(1): 1-8. |
| [4] | Halimeh Amiri, Farhad Ramezani-Badr, Naseh Sigari, Karim Nasseri. Comparative efficacy of honey 12.5% and chlorhexidine 0.2% mouthwashes on the oropharyngeal bacterial colonization in mechanically-ventilated patients: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2020, 40(3): 440-446. |
| [5] | Li Kai, Liu Rui, Xu Guangzhong, Zhang Weihua, Liu Chen, Zhu Bin, Hua Baojin, Feng Xingzhong. Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage Ⅲ colon cancer [J]. Journal of Traditional Chinese Medicine, 2019, 39(02): 251-257. |
| [6] | Song Junmin, Liu Hongxiang, Li Zhen, Yang Chao, Wang Chaojie. Ginsenoside Rg3 inhibits colon cancer cell migration by suppressing nuclear factor kappa B activity [J]. Journal of Traditional Chinese Medicine, 2015, 35(04): 440-444. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.
